Genzyme rare-disease drug gets priority label

Share this article:

The FDA granted priority review status to Genzyme's experimental, all-oral Gaucher's disease treatment Cerdelga (eliglustat).

The FDA's priority label means the regulator will decide for or against the twice-a-day pill within six months.

The Sanofi subsidiary said in a statement that the 400-patient clinical trial supporting the filing is the largest ever conducted for Gaucher's disease.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.